Cutaneous Hormonal Control of Melanocyte DNA Repair through Camp Signaling

Stuart G Jarrett and John A D'Orazio

Markey Cancer Center and the Departments of Pediatrics, University of Kentucky College of Medicine, USA

Corresponding author: John A D'Orazio, M.D., Ph.D., Associate Professor of Pediatrics, University of Kentucky College of Medicine, Markey Cancer Center, Combs Research Building 204, 800 Rose Street, Lexington, KY 40536-0096, USA, Tel: (859) 323-6238; Fax. (859) 257-8940; E-mail: jdonazio@uky.edu

Rec date: Mar 25, 2015; Acc date: Jun 04, 2015; Pub date: Jun 06, 2015

Copyright: © 2015 Jarrett SG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Melanoma is roughly 20 times more common in persons with fair complexion compared to those with darker skin tones [1]. Even among lightly-pigmented individuals, melanoma risk varies between people, being highest among those who burn rather than tan upon UV exposure [2]. Many of the same genes that regulate the tanning response also control how well melanocytes cope with UV damage [3]. Since UV is causative for a substantial portion of melanomas, melanoma risk is directly affected by melanocyte UV responses. We and others have been interested in the melanocortin signaling axis because the vigor of melanocortin responses is a major predictor of melanoma risk [4]. Melanocortin signaling is a hormonally active pathway in the skin initiated by two major melanocortins produced by the pituitary–adrenocorticotropic hormone (ACTH) and alpha-melanocortin stimulating hormone (α-MSH), both of which are also produced in the epidermis and upregulated after UV exposure [5]. Melanocortins influence melanocytes through a cell surface Gs-coupled receptor known as the melanocortin 1 receptor (MC1R). When bound by agonistic ligands (ACTH or α-MSH), the MC1R activates adenylyl cyclase which in turn generates the second messenger cAMP.

UV radiation has many effects on macromolecules and cells of the skin. Aside from the conversion of 7,8-dehydrocholesterol to previtamin D3, which is necessary for natural cutaneous production of vitamin D, most UV effects are deleterious to cells of the skin. UV promotes structural and chemical changes to proteins, RNA and lipids, however it is primarily through its effects on DNA that impact cancer risk. UV causes covalent changes to nucleotide bases within DNA by promoting structural and chemical changes to proteins, RNA and lipids. Worse, if the cell is not able to repair these “photoproducts” - cyclopyrimidine dimers and [6,4]-photoproducts–interfere with gene expression and replication by interfering with DNA polymerases. Worse, if the cell manages to replicate with photoproducts in place, then permanent “UV signature” mutations result in the daughter cells. These TT-to-CC and CC-to-TT dipyrimidine transitions are very commonly found in melanoma [7,8] therefore UV damage and mutagenesis are clearly linked with melanoma development.

From a public health standpoint, melanoma incidence has been steadily rising in the US for decades. Whereas roughly 1 in 1,500 Americans was diagnosed with melanoma in the 1930’s, today approximately 1 in 50 people (2% of the population) will develop melanoma at some point in his/her life. Many factors likely explain the increasing prevalence of disease including increased recreational sun exposure, better disease surveillance, an aging population and the proliferation of indoor tanning facilities. Though important therapeutic advances are being made in molecular targeting and immunotherapy against melanoma, the great majority of patients with advanced melanoma still die of their disease. Roughly 10,000 Americans now die of melanoma each year, and melanoma often affects young adults and people in the prime of life [1]. Therefore, there is a great need to understand early events in melanocyte carcinogenesis, particularly with regard to how melanocytes resist UV mutagenesis.

In recent years, we and others have noted that the melanocortin signaling axis controls not only skin pigment responses but also directly regulates melanocyte DNA repair [3,9-13]. When activated and functional, MC1R/CAMP signaling boosts the ability of melanocytes to rid their DNA of UV photoproducts. The mechanisms that mediate MC1R augmentation of melanocytic DNA repair responses have only recently begun to be defined. We recently reported that the critical molecular event linking MC1R signaling to DNA repair is a unique phosphorylation event of the global cell damage response protein “ataxia and rad3-related” (ATR). When CAMP levels are induced either by MSH-MC1R interactions or pharmacologically with adenylyl cyclase activation, cAMP-dependent protein kinase (PKA) becomes activated and phosphorylates ATR on its Serine 435 (S435) residue. This post-translational modification causes ATR to associate with a key DNA repair factor known as xeroderma pigmentosum A protein (XPA) [3], XPA is one of eight core proteins that make up the nucleotide excision repair (NER) pathway, the genome maintenance pathway charged with the removal of UV photoproducts to prevent UV mutagenesis. We found that XPA and pS435-ATR localize to UV photoproducts in a greatly accelerated and enhanced manner if melanocytes have been stimulated through MC1R signaling or cAMP activation (Figure 1).

![Figure 1: MC1R-mediated repair in melanocytes. cAMP generated from melanocortin signaling or through pharmacologic adenylyl cyclase activation promotes PKA-dependent ATR phosphorylation on S435 which binds to XPA, translocates to nuclear photodamage, and accelerates nucleotide excision repair (NER).](image-url)
S435 is part of a PKA target sequence (RRXS*) within ATRs predicted nuclear localization sequence (425-DGISPKRRLSSLNPSKRAP), suggesting that its phosphorylation might impact ATRs nuclear localization, possibly through interactions with nuclear importins [14]. Indeed, colocalization studies of p-S435 ATR and XPA suggest that PKA modification promotes nuclear entry of ATR-XPA in order to prime NER for DNA damage [3] and PKA-directed nuclear localization of DNA-PK, another PIKK family member, has also been reported [15]. Alternatively, PKA-mediated phosphorylation of ATR at S435 may optimize NER through enhanced intranuclear interactions with XPA to facilitate transport and/or assembly at sites of UV damage. Our findings suggest that PKA-mediated phosphorylation of ATR at S435 is an important event that dynamically regulates early recruitment and assembly of XPA and possibly other DNA repair proteins to sites of UV damage in order to optimize NER [3].

Melanocortin signaling may also impact genome stability through other mechanisms. MC1R, for example, is a key regulator of signaling mediators of the damage response such as p38, p53, ATR and ATM in response to UV [10,11], and others found that melanocortin-enhanced DNA repair was mediated by increased levels of the DNA damage recognition factor XPC as well as H2AX [12]. Additionally, MC1R signaling induced the transcription of the N4RA subfamily of nuclear receptors, which were recruited to sites of nuclear DNA damage together with XPC and XPE [16-18]. Thus, melanocortin/cAMP signaling represents a global regulator of melanocytic NER and genome maintenance.

These observations have many translational implications. Firstly, since MC1R signaling directly regulates melanocytic NER, people with inherited loss-of-signaling MC1R polymorphisms (very common among fair-skinned, UV-sensitive and melanoma-prone individuals) accumulate more UV mutations not just because of defective pigment production but also because of blunted NER. NER is exceptionally important for melanoma resistance, as evidenced by the natural history of patients with xeroderma pigmentosum (XP), who, because of defective NER caused by the homozygous loss of one of the core NER proteins (such as XPA), have up to a 2,000-fold increased risk of melanoma [19]. Therefore, we reason that blunted NER from MC1R dysfunction would also affect melanoma risk, albeit not to the extent of complete NER loss. Our data also suggest potential therapeutic implications. It may be possible to restore MC1R signaling in MC1R-defective individuals through pharmacologic manipulation of the MSH-MC1R signaling axis [9,20] and in so doing afford their melanocytes the many UV-protective benefits that cAMP signaling has to offer. Finally, we recently reported that physiologic MC1R hormonal antagonists agouti signaling protein (ASIP) and beta-defensin 3 (BD3) block and/or down-regulate the melanocortin signaling DNA repair axis [13], raising the possibility that melanocyte NER and subsequent melanoma risk may be controlled in part by the presence of MC1R antagonists, some of which are known to be induced by inflammation and infectious agents [21]. Discovering the molecular events that control these pathways will facilitate the informed development of rational and targeted melanoma-preventive strategies to reduce the risk of melanoma.

References


Page 2 of 3